Biocartis is latest European life sciences IPO hopeful
This article was originally published in Scrip
The molecular diagnostics technology specialist Biocartis, headed by seasoned Belgian biotech entrepreneur Rudi Pauwels, has announced plans to raise funds through an initial public offering list on Euronext Brussels. The firm launched its first commercial product, Idylla, in September 2014.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.